Effect of gabapentin versus placebo on delirium after surgery in patients with coronary artery bypass graft

Effect of gabapentin versus placebo on delirium after surgery in patients with coronary artery bypass graft: a double-blind randomized clinical trial

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20120215009014N393

Enrollment

Registered

2021-05-03

Start date

2021-05-05

Completion date

Unknown

Last updated

2021-05-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Delirium. Delirium due to known physiological condition

Interventions

Intervention 1: Intervention group: Two gabapentin capsules 400 mg (manufactured by Oxir Pharmaceutical Co.) 2 hours before surgery and then on gabapentin capsule 400 mg every 12 hours for 3 das. Inte

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: Age of 18 to 75 years, Candidate for coronary artery bypass graft,

Exclusion criteria

Exclusion criteria: Sensitivity to gabapentin medication

Design outcomes

Primary

Measure	Time frame
Measuring delirium. Timepoint: Before surgery and 3 days after that. Method of measurement: Using Visual Analog Scale (VAS).	—

Secondary

Measure	Time frame
Probable side effect including drowsiness, nausea and vomiting. Timepoint: up to 3 days after surgery. Method of measurement: By history taking.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Parya Sayarfar

Hamedan University of Medical Sciences

saiyarfar.paria@yahoo.com+98 81 3838 0572

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026